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Abstract
Purified polysaccharide and conjugate vaccines are widely used for preventing infections in adults and in children against
the Gram-positive bacterium Streptococcus pneumoniae, a pathogen responsible for high morbidity and mortality rates,
especially in developing countries. However, these polysaccharide-based vaccines have some important limitations, such as
being serotype-dependent, being subjected to losing efficacy because of serotype replacement and high manufacturing
complexity and cost. It is expected that protein-based vaccines will overcome these issues by conferring a broad coverage
independent of serotype and lowering production costs. In this study, we have applied the ‘‘shaving’’ proteomic approach,
consisting of the LC/MS/MS analysis of peptides generated by protease treatment of live cells, to a collection of 16
pneumococcal clinical isolates from adults, representing the most prevalent strains circulating in Spain during the last years.
The set of unique proteins identified in all the isolates, called ‘‘pan-surfome’’, consisted of 254 proteins, which included most
of the protective protein antigens reported so far. In search of new candidates with vaccine potential, we identified 32 that
were present in at least 50% of the clinical isolates analyzed. We selected four of them (Spr0012, Spr0328, Spr0561 and
SP670_2141), whose protection capacity has not yet been tested, for assaying immunogenicity in human sera. All of them
induced the production of IgM antibodies in infected patients, thus indicating that they could enter the pipeline for vaccine
studies. The pan-surfomic approach shows its utility in the discovery of new proteins that can elicit protection against
infectious microorganisms.
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Introduction
Streptococcus pneumoniae is a Gram-positive bacterium that can be
found as a commensal in the human respiratory tract and that,
under appropriate conditions, is pathogenic, being able to cause
high morbidity and mortality [1]. This microorganism is a leading
cause of mucosal diseases such as otitis media, sinusitis and
pneumonia and is a prominent pathogen in invasive diseases
including bacteremia, meningitis, and sepsis [2]. Pneumococcal
disease disproportionally affects young children and the elderly
although it may occur in all age groups and with higher frequency
among patients with co-morbid conditions. It has been estimated
that approximately 800,000 children die each year due to
pneumococcal disease and .90% of these deaths occur in
developing countries [3]. Burden of disease due to pneumococcal
diseases, generally related to pneumonia, is also high among adults
in developed countries with around 25,000 deaths per year in the
United States in adults over 50 years of age and significant
mortality and long-term effects on quality of life in European
countries [4,5].
Prevention of pneumococcal disease by immunization has long
been considered a major goal that could help to reduce the burden
of pneumococcal diseases and to control antimicrobial resistance
rates [6,7]. Two types of pneumococcal vaccines are available in
the market, both based on the capsule polysaccharide: pneumo-
coccal purified polysaccharide vaccine and conjugate vaccines, in
which polysaccharides are conjugated to a protein carrier capable
of recruiting CD4+ T-cells, increasing immunogenicity in young
children [8]. The first type is mainly used in adults, covering 23
capsule serotypes (Pneumovax 23V) that represent about 80% of
the most prevalent pneumococcal disease-causing ones in children
and adults in the USA [9]. A pneumococcal conjugate vaccine
covering 7 serotypes (PCV7) was initially licensed for exclusive use
in children, and new vaccines with broader serotype coverage
(10V and 13V) were later developed. The 13-valent pneumococcal
conjugate vaccine (PCV13) has been approved for prevention of
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invasive disease (FDA and EMEA) and pneumonia (FDA) caused
by PCV13 serotypes among adults aged 50 years and older, and
was recently recommended for adults aged $19 years with
immunocompromising conditions in the United States by ACIP
[10].
Although it seems that Pneumovax-23 protects effectively
against invasive pneumococcal disease (IPD) in healthy adults, its
efficacy in high-risk groups and against other outcomes (pneumo-
nia, mortality) is less clear [1]. In addition, and together with
conjugate vaccines, they present some important limitations [11]:
i) coverage is serotype-dependent, not covering the majority of the
93 capsule serotypes described so far; ii) coverage is designed on
the basis of the most prevalent serotypes identified in developed
countries and may be less effective in developing countries; iii)
vaccine effectiveness may decrease in the long term due to non-
vaccine serotype replacement [12]; iv) high manufacturing
complexity and cost make these vaccines less accessible to
developing countries; and v) genomic factors other than capsular
determinants may modulate virulence, and therefore it has been
suggested that a vaccine based on genetic factors other than
serotype may be necessary especially for otitis media and
nonbacteremic pneumonia [13]. Protein-based vaccines theoret-
ically offer advantages over those based on the capsule polysac-
charides, by allowing them to overcome the previously cited
problems: targeting conserved antigens in a serotype-independent
way, covering a broader pneumococcal biotype population, and
lowering cost of production [14]. Here, surface proteins are ideal
as they have the highest chance of raising an effective immune
response. So far, numerous pneumococcal proteins have shown
protection against infection in animal models, but most of them
are still in clinical trials. Proteomics provides excellent platforms
and strategies to identify in a fast and reliable way the set of
proteins expressed on the surface of pathogenic microorganisms.
To this regard, the ‘‘shaving’’ approach –consisting of treating live
cells with proteases, followed by LC/MS/MS analysis of the
generated peptides– has become a highly valuable tool when
searching for protein vaccine candidates [15,16]. In this study, we
have screened a collection of pneumococcal clinical isolates from
adults by defining its ‘‘pan-surfome’’, (i.e. the whole set of
expressed surface proteins), in order to identify which proteins that
have not been tested so far in animal models for protection against
infection could enter the vaccine pipeline in future studies.
Materials and Methods
Ethics Statement for Human Sera Sampling and Use
This research was performed according to the principles
expressed in the Declaration of Helsinki. All human sera were
obtained from patients .8 years old admitted to Hospital
Universitario Infantil Virgen del Rocı́o (HUIVR) in Seville,
Spain. Sera were drawn either from patients with a diagnosis of
pneumococcal infection, determined by isolation of the microor-
ganism from a sterile site (blood or pleural fluid) according to
standardised protocols or from healthy control children aged .8
years old. All sera from patients were obtained within ten days of
hospital admission. Written informed consent was obtained from
parents or legal guardians of participating children and the
Hospital Universitario Virgen del Rocı́o Ethic Committee
approved the study (code no. 010470, certificate no. 14/2010),
for sera to be used within the project in which this work was
designed.
Bacterial Strains and Growth
The 16 S. pneumoniae strains used in this study isolated from adult
patients corresponded to 9 different capsule serotypes (Table 1).
All the strains were maintained at 280uC, plated on Columbia
blood agar base containing 6% (v/v) sheep blood and grown in a
chemically-defined medium (CDM) [17] supplemented with
20 mg/ml ethanolamine (CDM+EA) as source of aminoalcohol,
at 37uC and 5% CO2 until OD600 of 0.25 (mid-exponential phase)
was reached.
Molecular Genotyping
MLST was performed using standard methodology [18]. In
brief, internal fragments of 7 housekeeping genes (aroE, gdh, gki,
recP, spi, xpt and ddl) were amplified by polymerase chain reaction
and sequenced on each strand. Conventional primers were used,
whose sequences are available at the MLST database (http://
www.mlst.net). Alleles were assigned by comparing the sequence at
each locus to all known alleles at that locus, and the combination
of 7 alleles determined the sequence type (ST). Allele and ST
designations were made using the MLST website, hosted at
Imperial College London, and funded by the Wellcome Trust.
‘‘Shaving’’ of Live Pneumococcal Cells with Trypsin
Generation and recovery of tryptic peptides from ‘‘shaved’’ cells
was carried out as described in [19] without modifications. Briefly,
100 ml of cultures were centrifuged at 3,5006g for 10 min at 4uC,
and the pelleted bacteria washed twice with PBS. Cells were
resuspended in one-hundredth volume of PBS/30% sucrose
(pH 7.4). Tryptic digestions were performed with 5 mg trypsin
(Promega) for 30 min at 37uC. The digestion mixtures were
centrifuged at 3,5006g for 10 min at 4uC, and the supernatants
(the ‘‘surfomes’’ containing the peptides) were filtered using 0.22-
mm pore-size filters (Milipore). Surfomes were re-digested with
2 mg trypsin overnight at 37uC with top-down agitation. Salts were
removed prior to analysis, using Oasis HLB extraction cartridges
(Waters). Peptides were eluted with increasing concentrations of
acetonitrile/0.1% formic acid, according to manufacturer’s
instructions. Peptide fractions were concentrated with a vacuum
concentrator (Eppendorf), and kept at 220uC until further
analysis.
LC/MS/MS Analysis
All analyses were performed with a Surveyor HPLC System in
tandem with an LTQ-Orbitrap mass spectrometer (Thermo Fisher
Scientific, San Jose, USA) equipped with nanoelectrospray
ionization interface (nESI), as described [19]. The separation
column was 150 mm60.150 mm ProteoPep2 C18 (New Objec-
tive, USA) at a postsplit flow rate of 1 ml/min. For trapping of the
digest a 5 mm60.3 mm precolumn Zorbax 300 SB-C18 (Agilent
Technologies, Germany) was used. One fourth of the total sample
volume, i.e. 5 ml, was trapped at a flow rate of 10 ml/min for 10
minutes and 5% acetonitrile/0.1% formic acid. After that, the
trapping column was switched on-line with the separation column
and the gradient was started. Peptides were eluted with a 60-min
gradient of 5–40% of acetonitrile/0.1% formic acid solution at a
250 nl/min flow rate. All separations were performed using a
gradient of 5–40% solvent B for 60 minutes. MS data (Full Scan)
were acquired in the positive ion mode over the 400–1,500 m/z
range. MS/MS data were acquired in dependent scan mode,
selecting automatically the five most intense ions for fragmenta-
tion, with dynamic exclusion set to on. In all cases, a nESI spray
voltage of 1.9 kV was used.
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Protein Identification by Database Searching
Tandem mass spectra were extracted using Thermo Proteome-
Discoverer 1.0 (Thermo Fisher Scientific). Charge state deconvo-
lution and deisotoping were not performed. All MS/MS samples
were analyzed using Sequest (Thermo Fisher Scientific, version
v.27), applying the following search parameters: peptide tolerance,
10 ppm; tolerance for fragment ions, 0.8 Da; b- and y-ion series;
oxidation of methionine and deamidation of asparagine and
glutamine were considered as variable modifications; maximum
trypsin missed cleavage sites, 3. The raw data were searched
against an in-house joint database containing the protein
sequences from all the sequenced and annotated S. pneumoniae
strains available at the NCBI ftp site. Peptide identifications were
accepted if they exceeded the filter parameter Xcorr score vs
charge state with SequestNode Probability Score (+1 = 1.5,
+2 = 2.0, +3 = 2.25, +4 = 2.5). With these search and filter
parameters, no false-positive hits were obtained. For proteins
identified from only one peptide, fragmentations were checked
manually. Strain R6 was used as reference for providing the
accession numbers of the identified proteins; whenever a protein
belonging to another strain was found, homology with a
corresponding protein of strain R6 was given by using protein-
BLAST. If homology with R6 or TIGR4 proteins was not
observed, then the protein accession numbers of the other strains
were used.
Bioinformatic Prediction of Protein Subcellular
Localization
Primary predictions of subcellular localization were assigned by
using the web-based algorithm LocateP (http://www.cmbi.ru.nl/
locatep-db/cgi-bin/locatepdb.py). They were contrasted by sev-
eral feature-based algorithms: TMHMM 2.0 (http://www.cbs.dtu.
dk/services/TMHMM-2.0) for searching transmembrane helices;
SignalP 3.0 (http://www.cbs.dtu.dk/services/SignalP) for type-I
signal peptides: those proteins containing only a cleavable type-I
signal peptide as featured sequence were classed as secreted; LipoP
(http://www.cbs.dtu.dk/services/LipoP) for identifying type-II
signal peptides, which are characteristic of lipoproteins. Topolog-
ical representations of membrane proteins were performed with
the web-based TOPO2 software (http://www.sacs.ucsf.edu/
TOPO2/). GO annotations were retrieved from the UniProt
Knowledgebase (http://www.uniprot.org/).
Western Blot Analysis
Immunoreactivity of pneumococcal proteins was performed by
Western blotting. 2 mg of pneumococcal recombinant proteins
Spr0328 and Spr0561, 5 mg of pneumococcal recombinant
proteins Spr0012, Spr0121, and SP670_2141 (produced as
GST-tag recombinant fragments using the pSparkH vector,
Canvax Biotech, Córdoba, Spain, and expressed in E. coli BL21.
See Dataset S1 for further details), 1 mg trypsin (Promega) as
negative control, and 1 mg of total protein extract of pneumococ-
cus as positive control were separated by 12% SDS-PAGE gels
and transferred to nitrocellulose membranes (Life Sciences). Non-
specific sites were blocked by incubation with 5% non-fat milk in
T-TBS for 1 h. After two washes with T-TBS, a second 1-h
incubation of the membranes with patient sera, diluted 1:100 in T-
TBS for IgG detection and 1:1,000 for IgM detection, was carried
out. Interference of IgG antibodies in IgM detection was avoided
using GullSORB TM (Meridian Bioscience, Inc.), according to
manufacturers’ instructions. Secondary antibodies consisted of
rabbit anti-human IgG or rabbit anti-human IgM conjugated to
horseradish peroxidase (Sigma), diluted 1:5,000 or 1:2,500 in TBS,
respectively, for 1 h. Then, the membranes were washed three
times with TBS and developed with ECL Plus Western Blotting
Dectection System (GE Healthcare) according to the manufactur-
er’s instructions.
Results and Discussion
We analyzed 16 clinical isolates collected from adult patients
with invasive pneumococcal disease (IPD). Nine different serotypes
were identified. These serotypes included the five most prevalent
ones found in IPD among older people in Spain during the most
recent years (19A, 3, 7F, 14 and 1), serotypes 9V and 19F that had
been circulating significantly in this population in pre- and post-
PCV7 periods, as well as serotypes 8 and 12F that were generally
restricted to adults and with epidemic potential [20,21]. We
genotyped all clinical isolates by MLST, because genetic diversity
of pneumococcal surface proteins depends on non-capsular
genomic background. Fifteen clonal types were found including
several major global clones recognized by the Pneumococcal
Molecular Epidemiology Network (PMEN) (http://www.sph.
emory.edu/PMEN) and genetically related genotypes as shown
in Table 1. The most relevant among them were: ST156 (Spain9V-
3), one of the most successful clones worldwide that has been
especially responsible for the expansion of serotype 14 in IPD in
various countries during recent years [22]; ST306 (Sweden1-28), a
highly circulating genotype associated with the increase in the
incidence of pleural empyema in children and adults in the last
Table 1. Sequence types (STs) and serotypes among 16




(MLST)* Serotype PMEN clone**
1 2480 12,8,4,5,18,58,18 9V
2 191 8,9,2,1,6,1,17 7F Netherlands7F-39
3 191 8,9,2,1,6,1,17 7F Netherlands7F-39
4 162 7,11,10,1,6,8,14 14 SLV-Spain9V-3***
5 228 12,8,1,5,17,4,20 1
6 433 1,1,4,1,18,58,17 19A
7 306 12,8,13,5,16,4,20 1 Sweden1-28
8 289 16,12,9,1,41,33,33 5 Colombia5-19
9 7340 2,5,36,12,17,21,271 8
10 1201 1,5,1,12,17,3,8 19A
11 156 7,11,10,1,6,8,1 14 Spain9V-3
12 180 7,15,2,10,6,1,22 3 Netherlands3-31
13 53 2,5,1,11, 16,3,14 8
14 557 7,11,10,1, 6,58,1 9V SLV-Spain9V-3***
15 1223 16,12,9,1,6,33,33 5 SLV-Colombia5-19***
16 989 12,5,89,8,6,112,14 12F
*Allelic profiles for each gene in multilocus sequence typing (MLST) are
presented in the following order: aroE, gdh, gki, recP,spi, xpt and ddl.
**PMEN clones are global clones recognized by pneumococcal molecular
epidemiology network.
***SLV = single locus variant (i.e. differs at only one MLST locus and thus is a
closely-related genotype).
doi:10.1371/journal.pone.0070365.t001
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decade [23,24]; ST289 (Colombia5-19), a highly relevant genotype
identified in IPD both in developing and developed countries and
associated with major local geographical outbreaks [25,26]; ST180
(Netherlands3-31), most commonly found clonal type in serotype 3
that is associated to increased risk of mortality in pneumococcal
pneumonia [27,28]; and finally, ST191 (Netherlands7F-39), the
dominant clonal type associated to the emerging serotype 7F
during the post-PCV7 period [29].
Interaction between cells and their environment is critically
mediated by surface proteins. In the case of pathogenic bacteria,
these molecules are often virulence factors or responsible for
pathogenesis. Since they also interact with the immune system,
many of them are highly immunogenic and are thus ideal targets
for novel vaccine discovery and development [30]. Protein-based
vaccines composed of a unique antigen or a combination of them
in a single formulation, may overcome the challenges remaining
with polysaccharide-based vaccines, such as serotype replacement
and high cost, thus making prophylaxis more affordable for
resource-limited populations [11].
To this regard, proteomics has been revealed as the best means
for high-throughput screening of large amounts of proteins for any
biological purpose, and in particular for defining the set of surface-
expressed proteins on a given organism. Several proteomic
analyses have been carried out on the pneumococcus, targeting
either the membrane fraction [31–33] or the cell wall-attached
proteins [34,35], but these biochemical fractionation-based
methods have several limitations: they are relatively slow,
membrane proteins are not always well resolved in polyacrylamide
gels and topology information is lost [19,36]. The ‘‘shaving’’
approach has become a powerful way to identify the set of surface
proteins expressed on a given organism (the ‘‘surfome’’), most of
which are normally highly immunogenic as shown by different
immunochemical techniques [15,16,37], and provides new candi-
dates that elicit protective activity against infection [38]. We have
previously set up this strategy in the pneumococcus [19], showing
that the procedure enables to define the ‘‘pan-surfome’’ of a
collection of clinical isolates, in order to select common proteins to
all or most strains [37,39].
We applied the optimized ‘‘shaving’’ protocol for pneumococ-
cus to the collection of adult clinical isolates, growing cells in a
chemically-defined medium with ethanolamine (CDM+EA) and
digesting them with trypsin for 30 min at 37uC. As already
described by our group [19], we have compared the efficiency of
the ‘‘shaving’’ procedure in different culture media. In the
complex Todd-Hewitt broth, 44 surface proteins were identified
at the described trypsin digestion conditions, compared to 32
found in CDM+EA; however, a higher percentage of cytoplasmic
proteins was found in THB than in CDM+EA (83% vs 61%).
Moreover, these differences were even higher when considering
identified peptides (in THB, only 15% corresponded to surface
Figure 1. Pan-surfomic analysis of pneumococcal adult clinical isolates. A) Yield of surface protein identification after trypsin treatment in
each of the 16 analyzed isolates. B) Subcellular localization of the predicted surface proteins, according to LocateP (TMD: transmembrane domain). C)
Gene Ontology annotations of the biological functions of the identified surface proteins. Numbers in panels B and C represent the proteins belonging
to each category.
doi:10.1371/journal.pone.0070365.g001
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proteins, whereas in CDM+EA this percentage was 43%). A total
of 254 surface proteins were identified in the set of the 16 isolates
(Table S1 and Datasets S2 and S3), and the yields of surface
protein identification ranged between 20% and 40%, approxi-
mately (Figure 1A). Within the different categories of surface
proteins recognized for Gram-positive bacteria, and particularly
Table 2. Identification of protective protein antigens against Streptococcus pneumoniae infection already described in literature.
Protein family Antigen Locus Location References Found in # strains
Choline-binding proteins PspA spr0121 1TMD [53] 14/16
CbpA (PspC) spr1995 Secreted [41] 16/16
PcpA spr1945 Secreted [45] 5/16
LytA spr1754 Cytoplasmic [47] 3/16
LytB spr0867 .1TMD [52] 7/16
Toxins Ply spr1739 Cytoplasmic [40] 6/16
Sortase and sortase-
dependent proteins
SrtA spr1098 1TMD [44] 4/16
RrgA SP_0462 Cell Wall [43] 0/16
RrgB SP_0463 Cell Wall [43] 0/16
RrgC SP_0464 Cell Wall [43] 0/16
NanA spr1536 Cell Wall [48] 13/16
SphtrA spr2045 1TMD [52] 11/16
ABC transporter proteins PiaA (ABC-SBP) spr0934 Lipoprotein [46] 2/16
PiuA (fecE) spr1686 Cytoplasmic [46] 2/16
PsaA spr1494 .1TMD [51] 2/16
PotD spr1243 1TMD [50] 1/16
sp0148 (ABC-SBP) spr0146 Lipoprotein [49] 5/16
Enzymatic proteins ClpP spr0656 Cytoplasmic [42] 1/16
StkP spr1577 1TMD [54] 1/16
FBA spr0530 Cytoplasmic [34] 13/16
gapA spr1825 Cytoplasmic [34] 16/16
eno spr1036 Cytoplasmic [56] 16/16
tig spr0362 Cytoplasmic [56] 9/16
ldh spr1100 Cytoplasmic [56] 11/16
pykF spr0797 Cytoplasmic [56] 15/16
pgk spr0441 Cytoplasmic [56] 15/16
gnd spr0335 Cytoplasmic [34] 13/16
Histidine triad proteins PhtA spr1061 Lipoprotein [55] 6/16
PhtB spr1060 Lipoprotein [55] 9/16
PhtD spr0907 1TMD [55] 14/16
PhtE spr0908 Secreted [55] 10/16
Others PcsB spr2021 Secreted [54] 12/16
PppA spr1430 Cytoplasmic [59] 6/16
PpmA (PrsA) spr0884 Lipoprotein [62] 8/16
SlrA spr0679 Cytoplasmic [60] 11/16
AmiA spr1707 Lipoprotein [61] 5/16
AliB spr1382 Lipoprotein [61] 9/16
AliA spr0327 Lipoprotein [61] 7/16
PfbB spr0075 Cell Wall [63] 8/16
PsrP sp_1772 Cell Wall [64] 0/16
spr0785 spr0785 Cytoplasmic [49] 1/16
spr1176 spr1176 Cytoplasmic [58] 1/16
spr2010 spr2010 .1TMD [58] 1/16
spr1875 spr1875 1TMD [57] 8/16
doi:10.1371/journal.pone.0070365.t002
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for streptococci, most of them (114+64 = 178, i.e. 70%) had some
transmembrane domain, 24 (9.4%) were predicted by LocateP as
secreted, 35 (13.8%) as lipoproteins and 17 (6.7%) as possessing an
LPXTG-anchoring motif to the cell wall (Figure 1B). Figure 1C
shows the GO annotations according to their biological function,
with a high number of proteins with unpredicted functions, which
make them highly interesting for further studies on molecular
characterization, participation in virulence or pathogenesis, or
assay of protection activity.
The ‘‘shaving’’ approach has already demonstrated its power
for identifying most of the previously discussed protective protein
antigens in other streptococcal species, even when the number of
clinical isolates used is low [15,16]. Our pan-surfomic analysis
included 40 out of the 44 proteins that have shown to induce
protection against pneumococcal infection [34,40–64] (Table 2).
Among these proteins, 13 are predicted as cytoplasmic. Although
many proteins pertaining to this category have been reported both
to be surface-located and to induce protection, the targets of our
analysis were those ones for which subcellular localization
algorithms predicts undoubtedly to be exported outside the cell.
Interestingly, we identified in a high proportion of clinical isolates
some of the best candidates described so far: the membrane
protein PspA [53] and the predicted extracellular proteins CbpA
[41] and PcsB [54]. Three out of the four protective antigens not
detected in our study were the pilin proteins RrgA, RrgB and
RrgC. Previous works have shown that Gram-positive pilus
subunit proteins are resistant to trypsin treatment [65], and
proteolysis with a non-specific protease such as proteinase K is
required to identify them [15,16,66,67].
To be considered as a promising vaccine candidate, a given
protein should ideally be surface-exposed, highly expressed, and
distributed as widely as possible [36] in order to overcome the
limitations of serotype-dependent polysaccharide vaccines [14].
However, experimentally identifying a high number of proteins
common to all the analyzed strains, can be a hard task. Actually,
Dreisbach et al. found in Staphylococcus aureus that only 7 proteins
(less than 10% of total identified) were common to the 4 isolates
analyzed [39]. We have reported very similar results in a low
number of pneumococcal strains (12 proteins, i.e. 10.5% of total,
in 5 isolates). But, as the number of analyzed isolates increases, the
probability of finding some proteins common to all of them
diminishes. In fact, we did not find any common protein to the 39
Streptococcus suis clinical isolates in a recent report [37]. In the
search for pneumococcal surface proteins to be proposed as
potential new vaccine candidates, we established a threshold for
the presence of a protein in at least 50% of the analyzed clinical
isolates; otherwise, a very stringent criterion would lead us to
identify the already described protective antigens. Thus, 32
proteins surpassed this threshold (Table 3). As expected, cell
wall-anchored, for which 10 proteins were identified, was the
category of surface proteins with the highest number of items
above this limit. Spr0075 was just identified in 50% of the isolates;
the other 9 cell-wall proteins were present in $11 strains. Three
lipoproteins were also found according to the selected criterion,
including the protective antigens PhtD and AliB (see Table 3), as
well as 7 proteins with one transmembrane domain (that included
protective antigens PspA and Spr1875) and other 7 proteins with
more than one transmembrane helix. Finally, 5 predicted proteins
to be secreted to the extracellular milieu were also found, including
the highly protective candidates CbpA and PcsB (annotated in the
R6 genome as Spr2021). As cell-wall proteins with the LPXTG-
anchoring motif are those most protruding and exposed on the
streptococcal surface [68], they are expected to be found most
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reported very similar results in the pan-surfome of 39 S. suis clinical
isolates, where 13 cell wall proteins (out of 17 identified, and out of
20 predicted in the database used) were identified in $50% of
strains [37].
Although predicted membrane proteins (i.e. those with $1
transmembrane domain) are normally the most abundant surface
protein group identified in ‘‘shaving’’ experiments, they represent
the lowest percentage compared to the corresponding total
number of predicted proteins in databases, compared to the other
groups [15,16,69]. Cell-wall anchored, secreted proteins and
lipoproteins are completely surface-exposed, except some small
regions embedded within the cell wall and/or the capsule.
Therefore, any portion of them would be a priori good for cloning
in order to produce recombinant fragments for vaccine testing (in
the case they were too large to select the whole sequence).
However, membrane proteins are theoretically more embedded
under the surface, and therefore their extracellular domains are
less exposed. In addition, those with more than one transmem-
brane domain are generally dificult to obtain in a recombinant
way, because of solubility problems. The best strategy to use them
in protection assays would consist of selecting those domains that
are experimentally confirmed to be surface-accessible. Figure 2
shows the peptides identified after LC/MS/MS analysis over the
topology predictions for the corresponding sequences of the 14
Figure 2. Topology representation of the predicted membrane proteins in the ‘‘pan-surfome’’ of the 16 S. pneumoniae clinical
isolates that have been identified in at least 50% of the analyzed strains. The TMHMM algorithm was used to predict transmembrane
domains (TMD) and signal peptides after prediction of subcellular localization by LocateP. In red are shown the peptides experimentally identified by
LC/MS/MS. A) Proteins with only one predicted TMD. B) Proteins with more than one TMD.
doi:10.1371/journal.pone.0070365.g002
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membrane proteins shown in Table 3. For 9 proteins, experi-
mental assignments of identified peptides were in agreement with
the predicted topologies (i.e. peptides corresponded to extracellu-
lar domains). However, for the other 5 proteins (Spr0086,
Spr0334, Spr0907, Spr1370 and Spr2045), discrepancies were
observed, as we identified peptides belonging to predicted
cytoplasmic domains. These disagreements have also been
reported in other works [16,69,70], although in S. pyogenes it has
been experimentally demonstrated by flow cytometry assays that
some of these predicted cytoplasmic domains are actually surface-
located [16], thus showing that prediction algorithms do not
always correctly predict the topology of all the membrane proteins.
Moreover, a deeper view on the identified peptides for each
individual isolate may provide ‘‘hot zones’’ (i.e. those identified in
many strains) that might be best for selection of cloning fragments,
in case of very large proteins (Dataset S4).
Finally, we evaluated the power of ‘‘pan-surfomics’’ for the
selection of protein antigens with vaccine potential, by measuring
the immunoreactivity in sera from infected patients. Thus, we
selected five proteins from those identified in common in at least
50% of the isolates, and performed a Western-blot analysis to
detect both IgG and IgM reaction. Of these proteins, four had not
previously been assayed for protection. We also selected PspA
(Spr0121), whose protection capacity against infection is well
known [53], to validate the utility of this approach. As a positive
control, we used a total protein extract from pneumococcus, and
as a negative control, commercially available trypsin. As shown in
Figure 3, IgG antibodies were raised against the five proteins,
even in the three sera used as healthy controls, which might be due
to previous asymptomatic pneumococcal colonization. Regarding
IgM response, two out of the three patients raised these antibodies
against the five selected proteins; the other patient (patient #1)
produced IgM antibodies against three proteins (Spr0121,
Spr0328 and Spr0561). The three healthy donors raised IgM
antibodies against Spr0561. In addition, control #3 showed anti-
Spr0012 IgM antibodies. As observed in the figure, both the IgG
and IgM responses against Spr0561 were very intense, which
could mean that it is strongly immunogenic. This high immuno-
genicity, which may be due to its highly surface exposure and size
(it is a 2,144-amino acid cell-wall protein) could be also responsible
for the presence of IgM antibodies in healthy donors if they had
been previously colonized by pneumococcus.
We have previously shown the utility of the detection of
immunoreactivity against selected surface proteins for the discov-
ery of diagnostic biomarkers of infection both in children and in
adults [19]. In that study, we demonstrated that five known
protective antigens raised antibodies in convalescent patients. In
addition, a cell-wall protein, the alkaline pullulanase PulA, not
previously tested at protection level, was shown to induce antibody
response. Here we show the potential of four novel surface
proteins (Spr0012, Spr0328, Spr0561 and SP670_2141) for
vaccine testing, because of their capacity to raise immune response
in infected patients. As expected, an IgM response against most of,
or all the selected proteins, was obtained in the infected patient
sera (2 out of 3), but much less in the control individuals (as stated
above, only against Spr0561 in the three healthy donors and
against Spr0012 in control #3). On the contrary, the five proteins
induced IgG production both in the infected and the control
people. The detection of IgG antibodies in healthy, control
individuals may be explained by non-symptomatic carriage, which
can mask a true discrimination among markers of disease.
Therefore, IgM detection should be a priori a better indicator of
antigen exposure. However, the lower levels of these antibodies
make them more difficult to detect, and factors such as timing in
taking the samples may represent some limitations [71]. More
sensitive, large scale formats for IgM-based protein antigen
detection are needed, as customized protein chips or Luminex
assays.
In conclusion, this study shows the utility of pan-surfomic
approach in the high-trhoughput screening of proteins that could
enter the pipeline for new vaccine discovery. The selection of the
candidates from the proteomic analysis must be complemented
with immunogenicity studies to determine the capacity of such
proteins to raise an effective immune response. Further research is
needed to test the protection capacity of the proposed proteins in
animal models of infection, either individually or as ‘‘antigen
cocktail’’ formulations. Although the main application field of such
an approach is the discovery of new protein vaccines, the
development of serological tools for detecting diagnostic biomark-
ers, and/or the application in programs of epidemiological
surveillance, is also very promising, especially if large-scale formats
(protein arrays, Luminex assays) are set up.
Figure 3. Western blot analysis of five selected surface proteins against human sera. Detection of both IgG (left) and IgM (right) was
carried out. In all the cases, antibody reaction was observed against the positive control (pneumococcal protein extract; see Materials and Methods
for further details), and no reaction against the negative control (trypsin; see Materials and Methods for further details).
doi:10.1371/journal.pone.0070365.g003
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Supporting Information
Table S1 Surface proteins identified in the 16 Streptococcus
pneumoniae clinical isolates analyzed. Shown are the locus
numbers, gi accession numbers, protein function descriptions,
subcellular localization according to LocateP, presence of the
proteins in each isolate, and number of isolates in which each
protein has been found.
(XLSX)
Dataset S1 Recombinant fragments produced in this work from
the selected gene products. In gray are highlighted the sequences
amplified (from the corresponding genes) and produced as
recombinant polypeptides (from the corresponding amino acid
sequences). Number of nucleotides amplified and amino acids
expressed are indicated for each protein, as well as primers used
for DNA amplification.
(PDF)
Dataset S2 Sequest raw data of protein and peptide identifica-
tions for S. pneumoniae clinical isolates 5074-5, 5104-8, 5231-9V,
5278-14, 5284-9V, 5330-7F, 5333-19A and 5334-8. Each isolate’s
data are given separately in one or more datasheets.
(XLS)
Dataset S3 Sequest raw data of protein and peptide identifica-
tions for S. pneumoniae clinical isolates 5335-5, 5337-7F, 5341-1,
5342-3, 5343-14, 5344-19A, 5345-1 and 5431-12F. Each isolate’s
data are given separately in one or more datasheets.
(XLS)
Dataset S4 Representation of the sequences identified belonging
to membrane proteins over the 50% threshold (see Table 3), and
their frequency in the ‘‘pan- surfome’’ of the 16 Streptococcus
pneumoniae clinical isolates analyzed.
(PDF)
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19. Olaya-Abril A, Gómez-Gascón L, Jiménez-Munguı́a I, Obando I, Rodrı́guez-
Ortega MJ (2012) Another turn of the screw in shaving Gram-positive bacteria:
Optimization of proteomics surface protein identification in Streptococcus
pneumoniae. J Proteomics 75: 3733–3746.
20. Ardanuy C, Marimón JM, Calatayud L, Giménez M, Alonso M, et al. (2012)
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